BelFIBRO® – HEPATIC RAPID TEST

THE LIVER, ENERGY SUPPLIER AND DETOXIFICATION ORGAN

The hepatic function is essential: without a liver we cannot live. It transforms more than 10,000 different metabolic products every day. The liver is a challenging task in daily diagnostics because its complex metabolic pathways and structures require a great deal of understanding. BelFIBRO is a quick test for the different stages of liver diseases. The test expands the possibilities of diagnosis in daily practice. We use a reliable marker in order to be able to diagnose the stages of the liver in a short time, without having our in-house laboratory in practice.

LIVER OR HEPATIC DISEASES HAVE COMPLEX CONDITIONS

A broad spectrum of complex diseases can affect the liver. Usually the laboratory values of the patient are first determined and, if necessary, even a liver biopsy with all possible complications is performed for the diagnosis of the liver parenchyma. In 2013, 29 million people in the European Region (EU) suffered from chronic liver disease. In Germany, about 980,000 people (m:f = 2:1) suffer from liver cirrhosis. In industrialised countries, alcohol is the main cause of liver cirrhosis (liver shrinkage), in Africa and Asia hepatitis B and hepatitis C are the main causes.

Risk examination of the liver
– shortly by the family physician

NEWS: SEARCH FOR NEW LABORATORY PARAMETERS

«Non-alcoholic fatty liver hepatitis or steatohepatitis (NASH) is classified as a “silent epidemic” which causes either no or only non-specific symptoms. “We therefore need blood parameters that tell us reliably whether a serious liver disease is present or whether it can be ruled out,” points out Prof. Dr. Elmar Aigner, University Hospital Salzburg. …» Read more: Non-Alcoholic-Fatty-Liver-Disease

Source: Weiß J, Rau M, Geier A: Non-alcoholic fatty liver disease-epidemiology, clincal course, investigation and treatment. Dtsch Arztebl Int 2014; 111: 447−52. DOI: 10.3238/arztebl.2014.0447

DIAGNOSTICS IN DAILY PRACTICE

With the lateral-flow test BelFIBRO, which is to be supplied with serum, you have the possibility in your practice to determine the liver status of your patients reliably and non-invasively on site without risk for screening examinations or also as a specific diagnostic agent for liver diseases that have already been diagnosed. The various liver stages from fatty liver to cirrhosis can be diagnosed with a reliability of approx. 94%.

With the lateral flow test, practicing physicians get a wide diagnostic window that is covered by only one test. Only a few minutes of testing time are necessary to significantly increase the diagnostic window and the patient’s chances of survival.

ABSTRAKT

Risk factors for liver diseases are heavy alcohol consumption, chronic infectious hepatitis, fatty liver (hepatic steatosis), male sex, impaired immune system (HIV, immunosuppressive drugs), insulin resistance (ß-cell dysfunction, increased intact proinsulin), age over 50 years.

The IVD biomarker correlates linearly with liver development from healthy organ (F0, ≤54 ng/ml) via fatty liver (F1, 54-79 ng/ml) and liver fibrosis (F2, F3, 80-134 ng/ml) to irreversible liver cirrhosis (≥135 ng/ml).

The test shows a qualitative result starting at level F2 and above. The quantitative values can be determined immediately in the field using a scanning device.

For use by healthcare professionals only.
Liver (front) with gallbladder Source: http://www.medicalgraphics.de/
Image of a fatty liver - Stage 1-2 of fatty Liver
Image of hepatic fibrosis - Stage F2 / F3
Liver cirrhosis - Stage 4